A Study of Speech-Language Development and Auditory Biomarkers with Bilateral Cochlear Implants users - A Study of Speech-Language Development and Auditory Biomarkers with Bilateral Cochlear Implants users

Start Date09 Nov 2023

Sponsor / Collaborator

Shizuoka Prefectural Hospital Organization

JPRN-UMIN000050634 / Completed

A single-center retrospective cohort study of preoperative expiratory capacity to pulmonary complications after esophageal cancer surgery. - A single-center retrospective cohort study of preoperative expiratory capacity to pulmonary complications after esophageal cancer surgery.

Start Date10 Mar 2023

Sponsor / Collaborator

Shizuoka Prefectural Hospital Organization

JPRN-UMIN000049537 / Completed

Validity of muscle mass assessment using ultrasound in patient with lower leg edema - Validity of muscle mass assessment using ultrasound in patient with lower leg edema

Start Date17 Nov 2022

Sponsor / Collaborator

Shizuoka Prefectural Hospital Organization

100 Clinical Results associated with Shizuoka Prefectural Hospital Organization

0 Patents (Medical) associated with Shizuoka Prefectural Hospital Organization

1,555

Literatures (Medical) associated with Shizuoka Prefectural Hospital Organization

01 Dec 2024·Journal of Infection and Chemotherapy

Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity

Article

Author: Takebayashi, Akira ; Utano, Tomoyuki ; Shoji, Kensuke ; Nakamura, Hidefumi ; Saito, Jumpei ; Kawai, Toshinao ; Ishikawa, Takashi ; Terao, Chikashi ; Miyairi, Isao ; Hikino, Keiko ; Matsui, Toshihiro ; Matsumoto, Kimikazu ; Mushiroda, Taisei ; Kato, Motohiro ; Tomizawa, Daisuke

BACKGROUNDVoriconazole pharmacokinetics (PK) are known to be affected by genetic polymorphisms of drug-metabolizing enzymes such as CYP2C19; however, such information is limited for the pediatric population. The primary aim of this study is to establish a voriconazole PK model incorporating CYP2C19 phenotypes in Japanese children with malignancy or inborn errors of immunity.METHODSCYP2C19 genotypes were assessed by whole-genome genotyping and defined as follows: *17/*17: ultrarapid metabolizer (URM), *1/*17: rapid metabolizer (RM), *1/*1:normal metabolizer (NM), *1/*2, *1/*3, *2/*17:intermediate metabolizer (IM), and *2/*2, *2/*3, *3/*3: poor metabolizer (PM). Population PK analysis was performed. The voriconazole serum concentration profile was described by a two-compartment model with first-order absorption, mixed linear and nonlinear (Michaelis-Menten) elimination.RESULTSVoriconazole concentration data were available from 60 patients with a median age of 5.3 years. The phenotypes predicted from CYP2C19 genotypes were RM in 1 (2 %), NM in 21 (35 %) patients, IM in 27 (45 %) patients, and PM in 11 (18 %) patients. Underlying diseases included 38 (63%) patients with hematological malignancy and 18 (30 %) patients with inborn errors of immunity. Among the CYP2C19 phenotypes, PM was predicted to show complete inhibition (the degree of V_max inhibition [V_{max, inh}] = 100 %; V_max = 0). The estimated parameters of V_max,inh were +0.8 higher in patients with gamma-glutamyl transpeptidase (γ-GTP) Grade 2 or higher and +2.7 higher when C-reactive protein (CRP) levels were 2.0 mg/dL or higher.CONCLUSIONCYP2C19 genetic polymorphisms, γ-GTP, and CRP affect V_max,inh of voriconazole in children with malignancy or inborn errors of immunity.

01 Nov 2024·Chemistry and Physics of Lipids

Evaluation of molecular interaction between intercellular lipid organization in human stratum corneum and terpenes using time-resolved synchrotron X-ray diffraction

Article

Author: Okada, Mayuko ; Hatta, Ichiro ; Iwano, Yuna ; Kagawa, Yoshiyuki ; Uchino, Tomonobu ; Miyazaki, Yasunori ; Nakajo, Michiaki ; Nakajyo, Michiaki ; Yumoto, Ryuji

The stratum corneum (SC) presents certain limitations for topical administration of medication, which can be overcome using penetration enhancers (PEs) such as terpene (TP). The SC is also crucial for maintaining the skin barrier and consists of two lamellar structures: the short periodicity phase (SPP) and long periodicity phase (LPP). In this study, we monitored changes in the X-ray diffraction peaks of the human SC, 30 min after TP application (neroridol, 1,8-cineol, and d-limonene). With the application of nerolidol, no significant changes were observed in the small-angle diffraction peak positions for the lamellar structure of SPP, but the integrated intensity decreased. On the contrary, when applying 1,8-cineole and d-limonene, a lower angle peak shift with broadening of the peak width of SPP diffraction peaks was observed for d-limonene than for 1,8-cineole, and the degree of peak shift and width broadening was greater for d-limonene than for 1,8-cineole. The diffraction peaks of LPP disappeared when 1,8-cineole and d-limonene were applied. These results indicate that the degree of interaction between the SC and TP differs depending on the molecular species, and d-limonene and 1,8-cineole exhibit penetration-enhancing via lamellar structure disruption of both SPP and LPP, immediately after application.

01 Oct 2024·Cell

Neoself-antigens are the primary target for autoreactive T cells in human lupus

Article

Author: Nakai, Wataru ; Kanda, Teru ; Murata, Takayuki ; Tanzawa, Kaito ; Terao, Chikashi ; Okuzaki, Daisuke ; Arase, Noriko ; Kohyama, Masako ; Yasumizu, Yoshiaki ; Mori, Shunsuke ; Fujimoto, Manabu ; Suenaga, Tadahiro ; Naito, Ryota ; Kishida, Kazuki ; Motooka, Daisuke ; Kumanogoh, Atsushi ; Ogawa, Yoshihiro ; Kawada, Shoji ; Jin, Hui ; Arase, Hisashi ; Sakaguchi, Shimon ; Ohmura, Koichiro ; Kurosaki, Tomohiro ; Shishido, Tatsuya ; Nishide, Masayuki ; Tada, Asa

Major histocompatibility complex class II (MHC-II) is the most significant genetic risk factor for systemic lupus erythematosus (SLE), but the nature of the self-antigens that trigger autoimmunity remains unclear. Unusual self-antigens, termed neoself-antigens, are presented on MHC-II in the absence of the invariant chain essential for peptide presentation. Here, we demonstrate that neoself-antigens are the primary target for autoreactive T cells clonally expanded in SLE. When neoself-antigen presentation was induced by deleting the invariant chain in adult mice, neoself-reactive T cells were clonally expanded, leading to the development of lupus-like disease. Furthermore, we found that neoself-reactive CD4⁺ T cells were significantly expanded in SLE patients. A high frequency of Epstein-Barr virus reactivation is a risk factor for SLE. Neoself-reactive lupus T cells were activated by Epstein-Barr-virus-reactivated cells through downregulation of the invariant chain. Together, our findings imply that neoself-antigen presentation by MHC-II plays a crucial role in the pathogenesis of SLE.

100 Deals associated with Shizuoka Prefectural Hospital Organization

100 Translational Medicine associated with Shizuoka Prefectural Hospital Organization

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Shizuoka Prefectural Hospital Organization

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 17 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing